(Q42171217)

17 October 2017

title

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation (English)

1 reference

17 October 2017

1 reference

Louis Kuritzky

1

1 reference

17 October 2017

Benjamin J Epstein

series ordinal

2

1 reference

17 October 2017

Frank Lavernia

series ordinal

3

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

17 October 2017

published in

Postgraduate Medicine

1 reference

17 October 2017

volume

122

1 reference

17 October 2017

issue

3

1 reference

17 October 2017

page(s)

33-42

1 reference

A diabetes report card for the United States: quality of care in the 1990s

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

The burden of treatment failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Narrative review: a rational approach to starting insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICT

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Basal insulin or premix analogue therapy in type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Contributions of weekly mean blood glucose values to hemoglobin A1c in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

21 January 2018

Managing chronic disease

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Low-dose combination therapy: an important first-line treatment in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

Evolving strategies for the use of combination therapy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2140

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2140

1 reference

17 October 2017

1 reference